The US Food and Drug Administration approved VIZZ, the first prescription eye drop, made of acycidine, and is designed to treat aging, a common view of age linked to age that affects more than 128 million Americans.
VIZZ, developed by Lenz, is offered up to 10 hours of improving the nearby vision with one daily dose, which may reduce the need for reading glasses or dual -focal glasses.
Unlike previous treatments such as Vuity, which may cause weak vision and heaviness in the eyebrows, VIZZ only focuses on the pupil, and avoids the great motivation of the cordial muscle, which reduces side effects and rare complications.
The approval came after the results of three random trial trial trials of the second stage, including hundreds of participants, and more than 30,000 days of treatment without any serious side effects.
By overcoming the defects of the previous drug roads, VIZZ represents a new choice for millions of people seeking a clearer vision without totally relying on corrective lenses.
Lenz plans to provide these medical drops throughout the country in late 2025.
